Protocol
Tissue Repair
Thymosin Alpha-1 Immune Protocol [2026]
Thymic peptide research for immune modulation, T-cell differentiation, and antiviral immune enhancement.
Compounds
Thymosin Alpha-1
Dose: 1.6 mg
Freq: Twice weekly
Recon: 5mg + 1mL BAC
Conc: 5 mg/mL
Draw: 32 units (U-100)
Calculate Thymosin Alpha-1 dose
Protocol Phases
Loading Phase
Weeks 1 to 6
1.6 mg subcutaneous twice weekly. Clinically tested dose from hepatitis and cancer immune support trials. SubQ in abdomen or thigh.
Maintenance
Weeks 7 to 12
1.6 mg subcutaneous once weekly. Some protocols hold at 1.6 mg twice weekly for the full 12 weeks for active immune challenges.
FAQ
What does Thymosin Alpha-1 do?
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide from the thymus gland. It promotes T-cell maturation and differentiation, enhances natural killer cell activity, and modulates Th1/Th2 balance. It is approved in some countries for hepatitis B and C and cancer adjuvant therapy.
Is Thymosin Alpha-1 the same as Thymosin Beta-4 (TB-500)?
No. They are different peptides with different mechanisms. Thymosin Alpha-1 acts on immune cell differentiation and is a thymic immune modulator. Thymosin Beta-4 (TB-500) acts on actin dynamics and tissue repair. They are from the same thymosin family but have distinct research applications.
Can Thymosin Alpha-1 be stacked with other peptides?
Yes. Common research stacks include Thymosin Alpha-1 with BPC-157 for combined immune and tissue repair support, and with Epithalon for longevity immune applications. The compounds are typically injected at different times of day.
What is the clinical dose of Thymosin Alpha-1?
The clinically studied dose from Zadaxin (the approved pharmaceutical form of Thymosin Alpha-1) is 1.6 mg subcutaneous twice weekly. This is the basis for most research protocols. Some protocols use 3.2 mg twice weekly for intensive immune challenges.
Research Notes
- The 1.6 mg dose is derived from clinical trial data. Do not significantly exceed this without specific research justification.
- SubQ injection only. Not intended for IV administration in research settings.
- Reconstitute with bacteriostatic water. Refrigerate after reconstitution. Use within 30 days.
Related Protocols
For research use only. Not medical advice.